{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T05:38:39Z","timestamp":1788068319050,"version":"build-2784847793"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172878"],"award-info":[{"award-number":["82172878"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82373435"],"award-info":[{"award-number":["82373435"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2026,6,20]]},"DOI":"10.1038\/s41416-026-03364-7","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T07:53:26Z","timestamp":1775721206000},"page":"1704-1715","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["ITGB4 up-regulated by STAT3 reduces the sensitivity of bladder cancer to cisplatin by suppressing p53"],"prefix":"10.1038","volume":"134","author":[{"given":"Zhuo","family":"Xing","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7663-1533","authenticated-orcid":false,"given":"Haozhe","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingxia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulong","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuai","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiejun","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5249-3172","authenticated-orcid":false,"given":"Yuan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3114-9214","authenticated-orcid":false,"given":"Yongbao","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"3364_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"3364_CR2","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1038\/s41572-023-00468-9","volume":"9","author":"L Dyrskjot","year":"2023","unstructured":"Dyrskjot L, Hansel DE, Efstathiou JA, Knowles MA, Galsky MD, Teoh J, et al. Bladder cancer. Nat Rev Dis Primers. 2023;9:58.","journal-title":"Nat Rev Dis Primers"},{"key":"3364_CR3","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41585-019-0208-0","volume":"16","author":"C Alifrangis","year":"2019","unstructured":"Alifrangis C, McGovern U, Freeman A, Powles T, Linch M. Molecular and histopathology directed therapy for advanced bladder cancer. Nat Rev Urol. 2019;16:465\u201383.","journal-title":"Nat Rev Urol"},{"key":"3364_CR4","doi-asserted-by":"publisher","first-page":"1980","DOI":"10.1001\/jama.2020.17598","volume":"324","author":"AT Lenis","year":"2020","unstructured":"Lenis AT, Lec PM, Chamie K, Mshs MD. Bladder cancer: a review. JAMA. 2020;324:1980\u201391.","journal-title":"JAMA"},{"key":"3364_CR5","first-page":"404","volume":"70","author":"VG Patel","year":"2020","unstructured":"Patel VG, Oh WK, Galsky MD. Treatment of muscle-invasive and advanced bladder cancer in 2020. CA Cancer J Clin. 2020;70:404\u201323.","journal-title":"CA Cancer J Clin"},{"key":"3364_CR6","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2013.428","volume":"5","author":"L Galluzzi","year":"2014","unstructured":"Galluzzi L, Vitale I, Michels J, Brenner C, Szabadkai G, Harel-Bellan A, et al. Systems biology of cisplatin resistance: past, present and future. Cell Death Dis. 2014;5:e1257.","journal-title":"Cell Death Dis"},{"key":"3364_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.drup.2023.100938","volume":"68","author":"F Li","year":"2023","unstructured":"Li F, Zheng Z, Chen W, Li D, Zhang H, Zhu Y, et al. Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms. Drug Resist Updat. 2023;68:100938.","journal-title":"Drug Resist Updat"},{"key":"3364_CR8","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1038\/s41573-022-00571-8","volume":"22","author":"O Hassin","year":"2023","unstructured":"Hassin O, Oren M. Drugging p53 in cancer: one protein, many targets. Nat Rev Drug Discov. 2023;22:127\u201344.","journal-title":"Nat Rev Drug Discov"},{"key":"3364_CR9","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.7150\/thno.29673","volume":"9","author":"X Zhang","year":"2019","unstructured":"Zhang X, Qi Z, Yin H, Yang G. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1alpha-mediated regulation of apoptosis and autophagy. Theranostics. 2019;9:1096\u2013114.","journal-title":"Theranostics"},{"key":"3364_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.103768","volume":"99","author":"J Ma","year":"2020","unstructured":"Ma J, Li L, Yue K, Li Y, Liu H, Wang PG, et al. Bromocoumarinplatin, targeting simultaneously mitochondria and nuclei with p53 apoptosis pathway to overcome cisplatin resistance. Bioorg Chem. 2020;99:103768.","journal-title":"Bioorg Chem"},{"key":"3364_CR11","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3892\/ol.2014.2108","volume":"8","author":"D Abat","year":"2014","unstructured":"Abat D, Demirhan O, Inandiklioglu N, Tunc E, Erdogan S, Tastemir D, et al. Genetic alterations of chromosomes, p53 and p16 genes in low- and high-grade bladder cancer. Oncol Lett. 2014;8:25\u201332.","journal-title":"Oncol Lett"},{"key":"3364_CR12","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1038\/nrurol.2014.129","volume":"11","author":"W Choi","year":"2014","unstructured":"Choi W, Czerniak B, Ochoa A, Su X, Siefker-Radtke A, Dinney C, et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat Rev Urol. 2014;11:400\u201310.","journal-title":"Nat Rev Urol"},{"key":"3364_CR13","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.ccr.2014.01.009","volume":"25","author":"W Choi","year":"2014","unstructured":"Choi W, Porten S, Kim S, Willis D, Plimack ER, Hoffman-Censits J, et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014;25:152\u201365.","journal-title":"Cancer Cell"},{"key":"3364_CR14","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.cell.2017.09.007","volume":"171","author":"AG Robertson","year":"2017","unstructured":"Robertson AG, Kim J, Al-Ahmadie H, Bellmunt J, Guo G, Cherniack AD, et al. Comprehensive molecular characterization of muscle-invasive bladder cancer. Cell. 2017;171:540\u201356.e25.","journal-title":"Cell"},{"key":"3364_CR15","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1158\/0008-5472.CAN-19-1145","volume":"80","author":"S Ruan","year":"2020","unstructured":"Ruan S, Lin M, Zhu Y, Lum L, Thakur A, Jin R, et al. Integrin \u03b24-targeted cancer immunotherapies inhibit tumor growth and decrease metastasis. Cancer Res. 2020;80:771\u201383.","journal-title":"Cancer Res"},{"key":"3364_CR16","doi-asserted-by":"publisher","first-page":"6823","DOI":"10.1002\/cam4.4216","volume":"10","author":"X Jiang","year":"2021","unstructured":"Jiang X, Wang J, Wang M, Xuan M, Han S, Li C, et al. ITGB4 as a novel serum diagnosis biomarker and potential therapeutic target for colorectal cancer. Cancer Med. 2021;10:6823\u201334.","journal-title":"Cancer Med"},{"key":"3364_CR17","doi-asserted-by":"publisher","DOI":"10.7717\/peerj.8299","volume":"7","author":"P Wu","year":"2019","unstructured":"Wu P, Wang Y, Wu Y, Jia Z, Song Y, Liang N. Expression and prognostic analyses of ITGA11, ITGB4 and ITGB8 in human non-small cell lung cancer. PeerJ. 2019;7:e8299.","journal-title":"PeerJ"},{"key":"3364_CR18","first-page":"106","volume":"20","author":"X Meng","year":"2020","unstructured":"Meng X, Liu P, Wu Y, Liu X, Huang Y, Yu B, et al. Integrin beta 4 (ITGB4) and its tyrosine-1510 phosphorylation promote pancreatic tumorigenesis and regulate the MEK1-ERK1\/2 signaling pathway. Bosn J Basic Med Sci. 2020;20:106\u201316.","journal-title":"Bosn J Basic Med Sci"},{"key":"3364_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101166","volume":"4","author":"Y Qu","year":"2023","unstructured":"Qu Y, Yao Z, Xu N, Shi G, Su J, Ye S, et al. Plasma proteomic profiling discovers molecular features associated with upper tract urothelial carcinoma. Cell Rep Med. 2023;4:101166.","journal-title":"Cell Rep Med"},{"key":"3364_CR20","doi-asserted-by":"publisher","first-page":"RP88483","DOI":"10.7554\/eLife.88483.3","volume":"12","author":"H Fang","year":"2023","unstructured":"Fang H, Ren W, Cui Q, Liang H, Yang C, Liu W, et al. Integrin \u03b24 promotes DNA damage-related drug resistance in triple-negative breast cancer via TNFAIP2\/IQGAP1\/RAC1. eLife. 2023;12:RP88483.","journal-title":"eLife"},{"key":"3364_CR21","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.1111\/febs.14749","volume":"286","author":"L Yuan","year":"2019","unstructured":"Yuan L, Du X, Tang S, Wu S, Wang L, Xiang Y, et al. ITGB4 deficiency induces senescence of airway epithelial cells through p53 activation. FEBS J. 2019;286:1191\u2013203.","journal-title":"FEBS J"},{"key":"3364_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2023.107302","volume":"26","author":"L Guo","year":"2023","unstructured":"Guo L, Mohanty A, Singhal S, Srivastava S, Nam A, Warden C, et al. Targeting ITGB4\/SOX2-driven lung cancer stem cells using proteasome inhibitors. iScience. 2023;26:107302.","journal-title":"iScience"},{"key":"3364_CR23","doi-asserted-by":"publisher","first-page":"63870","DOI":"10.18632\/oncotarget.11563","volume":"7","author":"BH Park","year":"2016","unstructured":"Park BH, Lim JE, Jeon HG, Seo SI, Lee HM, Choi HY, et al. Curcumin potentiates antitumor activity of cisplatin in bladder cancer cell lines via ROS-mediated activation of ERK1\/2. Oncotarget. 2016;7:63870\u201386.","journal-title":"Oncotarget"},{"key":"3364_CR24","doi-asserted-by":"publisher","first-page":"2500","DOI":"10.1038\/sj.onc.1209162","volume":"25","author":"J Watanabe","year":"2006","unstructured":"Watanabe J, Nishiyama H, Matsui Y, Ito M, Kawanishi H, Kamoto T, et al. Dicoumarol potentiates cisplatin-induced apoptosis mediated by c-Jun N-terminal kinase in p53 wild-type urogenital cancer cell lines. Oncogene. 2006;25:2500\u20138.","journal-title":"Oncogene"},{"key":"3364_CR25","doi-asserted-by":"publisher","first-page":"28514","DOI":"10.18632\/oncotarget.25530","volume":"9","author":"S Pandey","year":"2018","unstructured":"Pandey S, Bourn J, Cekanova M. Mutations of p53 decrease sensitivity to the anthracycline treatments in bladder cancer cells. Oncotarget. 2018;9:28514\u201331.","journal-title":"Oncotarget"},{"key":"3364_CR26","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2020.606123","volume":"8","author":"KW Luo","year":"2020","unstructured":"Luo KW, Zhu XH, Zhao T, Zhong J, Gao HC, Luo XL, et al. EGCG enhanced the anti-tumor effect of doxorubicin in bladder cancer via NF-kappaB\/MDM2\/p53 pathway. Front Cell Dev Biol. 2020;8:606123.","journal-title":"Front Cell Dev Biol"},{"key":"3364_CR27","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1016\/j.freeradbiomed.2023.09.017","volume":"208","author":"D Gao","year":"2023","unstructured":"Gao D, Wang R, Gong Y, Yu X, Niu Q, Yang E, et al. CAB39 promotes cisplatin resistance in bladder cancer via the LKB1-AMPK-LC3 pathway. Free Radic Biol Med. 2023;208:587\u2013601.","journal-title":"Free Radic Biol Med"},{"key":"3364_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2105-9-559","volume":"9","author":"P Langfelder","year":"2008","unstructured":"Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinform. 2008;9:559.","journal-title":"BMC Bioinform"},{"key":"3364_CR29","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.7150\/thno.29673","volume":"9","author":"X Zhang","year":"2019","unstructured":"Zhang X, Qi Z, Yin H, Yang G. Interaction between p53 and Ras signaling controls cisplatin resistance via HDAC4- and HIF-1\u03b1-mediated regulation of apoptosis and autophagy. Theranostics. 2019;9:1096\u2013114.","journal-title":"Theranostics"},{"key":"3364_CR30","doi-asserted-by":"publisher","first-page":"295","DOI":"10.3892\/mmr.2014.2764","volume":"11","author":"D Yan","year":"2015","unstructured":"Yan D, Zheng X, Tu L, Jia J, Li Q, Cheng L, et al. Knockdown of Merm1\/Wbscr22 attenuates sensitivity of H460 non-small cell lung cancer cells to SN-38 and 5-FU without alteration to p53 expression levels. Mol Med Rep. 2015;11:295\u2013302.","journal-title":"Mol Med Rep"},{"key":"3364_CR31","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1089\/hum.2017.186","volume":"29","author":"L Dai","year":"2018","unstructured":"Dai L, Pan Q, Peng Y, Huang S, Liu J, Chen T, et al. p53 plays a key role in the apoptosis of human ovarian cancer cells induced by adenovirus-mediated CRM197. Hum Gene Ther. 2018;29:916\u201326.","journal-title":"Hum Gene Ther"},{"key":"3364_CR32","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.canlet.2016.03.023","volume":"376","author":"C Leng","year":"2016","unstructured":"Leng C, Zhang ZG, Chen WX, Luo HP, Song J, Dong W, et al. An integrin beta4-EGFR unit promotes hepatocellular carcinoma lung metastases by enhancing anchorage independence through activation of FAK-AKT pathway. Cancer Lett. 2016;376:188\u201396.","journal-title":"Cancer Lett"},{"key":"3364_CR33","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s11060-009-9844-1","volume":"92","author":"T Amano","year":"2009","unstructured":"Amano T, Nakamizo A, Mishra SK, Gumin J, Shinojima N, Sawaya R, et al. Simultaneous phosphorylation of p53 at serine 15 and 20 induces apoptosis in human glioma cells by increasing expression of pro-apoptotic genes. J Neurooncol. 2009;92:357\u201371.","journal-title":"J Neurooncol"},{"key":"3364_CR34","doi-asserted-by":"publisher","first-page":"e62527","DOI":"10.1371\/journal.pone.0062527","volume":"8","author":"X Zhang","year":"2013","unstructured":"Zhang X, Jia D, Liu H, Zhu N, Zhang W, Feng J, et al. Identification of 5-Iodotubercidin as a genotoxic drug with anti-cancer potential. PLoS ONE. 2013;8:e62527.","journal-title":"PLoS ONE"},{"key":"3364_CR35","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/nrc3430","volume":"13","author":"M Wade","year":"2013","unstructured":"Wade M, Li YC, Wahl GM. MDM2, MDMX and p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 2013;13:83\u201396.","journal-title":"Nat Rev Cancer"},{"key":"3364_CR36","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1124\/mol.119.117564","volume":"97","author":"X Xie","year":"2020","unstructured":"Xie X, He G, Siddik ZH. Cisplatin in combination with MDM2 inhibition downregulates Rad51 recombinase in a bimodal manner to inhibit homologous recombination and augment tumor cell kill. Mol Pharmacol. 2020;97:237\u201349.","journal-title":"Mol Pharmacol"},{"key":"3364_CR37","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1002\/ijc.27832","volume":"132","author":"R Mir","year":"2013","unstructured":"Mir R, Tortosa A, Martinez-Soler F, Vidal A, Condom E, P\u00e9rez-Perarnau A, et al. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells. Int J Cancer. 2013;132:1525\u201336.","journal-title":"Int J Cancer"},{"key":"3364_CR38","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s12551-013-0124-0","volume":"6","author":"LR Anderson","year":"2014","unstructured":"Anderson LR, Owens TW, Naylor MJ. Structural and mechanical functions of integrins. Biophys Rev. 2014;6:203\u201313.","journal-title":"Biophys Rev"},{"key":"3364_CR39","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.ccell.2019.01.007","volume":"35","author":"J Cooper","year":"2019","unstructured":"Cooper J, Giancotti FG. Integrin signaling in cancer: mechanotransduction, stemness, epithelial plasticity, and therapeutic resistance. Cancer Cell. 2019;35:347\u201367.","journal-title":"Cancer Cell"},{"key":"3364_CR40","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.ade3816","volume":"9","author":"A Mohanty","year":"2023","unstructured":"Mohanty A, Nam A, Srivastava S, Jones J, Lomenick B, Singhal SS, et al. Acquired resistance to KRAS G12C small-molecule inhibitors via genetic\/nongenetic mechanisms in lung cancer. Sci Adv. 2023;9:eade3816.","journal-title":"Sci Adv"},{"key":"3364_CR41","doi-asserted-by":"publisher","DOI":"10.1080\/15384047.2024.2314324","volume":"25","author":"D Ma","year":"2024","unstructured":"Ma D, Liu S, Liu K, Kong L, Xiao L, Xin Q, et al. MDFI promotes the proliferation and tolerance to chemotherapy of colorectal cancer cells by binding ITGB4\/LAMB3 to activate the AKT signaling pathway. Cancer Biol Ther. 2024;25:2314324.","journal-title":"Cancer Biol Ther"},{"key":"3364_CR42","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","volume":"740","author":"S Dasari","year":"2014","unstructured":"Dasari S, Tchounwou PB. Cisplatin in cancer therapy: molecular mechanisms of action. Eur J Pharmacol. 2014;740:364\u201378.","journal-title":"Eur J Pharmacol"},{"key":"3364_CR43","doi-asserted-by":"publisher","DOI":"10.1016\/j.bcp.2022.115323","volume":"206","author":"AMP Romani","year":"2022","unstructured":"Romani AMP. Cisplatin in cancer treatment. Biochem Pharmacol. 2022;206:115323.","journal-title":"Biochem Pharmacol"},{"key":"3364_CR44","doi-asserted-by":"publisher","first-page":"10064","DOI":"10.3390\/ijms231710064","volume":"23","author":"T Shimada","year":"2022","unstructured":"Shimada T, Yabuki Y, Noguchi T, Tsuchida M, Komatsu R, Hamano S, et al. The distinct roles of LKB1 and AMPK in p53-dependent apoptosis induced by cisplatin. Int J Mol Sci. 2022;23:10064.","journal-title":"Int J Mol Sci"},{"key":"3364_CR45","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1093\/annonc\/mdg071","volume":"14","author":"H Sultana","year":"2003","unstructured":"Sultana H, Kigawa J, Kanamori Y, Itamochi H, Oishi T, Sato S, et al. Chemosensitivity and p53-Bax pathway-mediated apoptosis in patients with uterine cervical cancer. Ann Oncol. 2003;14:214\u20139.","journal-title":"Ann Oncol"},{"key":"3364_CR46","first-page":"1069","volume":"62","author":"T Shono","year":"2002","unstructured":"Shono T, Tofilon PJ, Schaefer TS, Parikh D, Liu TJ, Lang FF. Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation. Cancer Res. 2002;62:1069\u201376.","journal-title":"Cancer Res"},{"key":"3364_CR47","doi-asserted-by":"publisher","first-page":"13777","DOI":"10.1073\/pnas.96.24.13777","volume":"96","author":"NH Chehab","year":"1999","unstructured":"Chehab NH, Malikzay A, Stavridi ES, Halazonetis TD. Phosphorylation of Ser-20 mediates stabilization of human p53 in response to DNA damage. Proc Natl Acad Sci USA. 1999;96:13777\u201382.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3364_CR48","first-page":"1001","volume":"1","author":"UM Moll","year":"2003","unstructured":"Moll UM, Petrenko O. The MDM2-p53 interaction. Mol Cancer Res. 2003;1:1001\u20138.","journal-title":"Mol Cancer Res"},{"key":"3364_CR49","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1007\/s00109-009-0525-5","volume":"87","author":"R Amato","year":"2009","unstructured":"Amato R, D\u2019Antona L, Porciatti G, Agosti V, Menniti M, Rinaldo C, et al. Sgk1 activates MDM2-dependent p53 degradation and affects cell proliferation, survival, and differentiation. J Mol Med. 2009;87:1221\u201339.","journal-title":"J Mol Med"},{"key":"3364_CR50","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-019-1635-9","volume":"10","author":"Y Ning","year":"2019","unstructured":"Ning Y, Hui N, Qing B, Zhuo Y, Sun W, Du Y, et al. ZCCHC10 suppresses lung cancer progression and cisplatin resistance by attenuating MDM2-mediated p53 ubiquitination and degradation. Cell Death Dis. 2019;10:414.","journal-title":"Cell Death Dis"},{"key":"3364_CR51","doi-asserted-by":"publisher","first-page":"8921","DOI":"10.18632\/oncotarget.13475","volume":"8","author":"K Hientz","year":"2017","unstructured":"Hientz K, Mohr A, Bhakta-Guha D, Efferth T. The role of p53 in cancer drug resistance and targeted chemotherapy. Oncotarget. 2017;8:8921\u201346.","journal-title":"Oncotarget"},{"key":"3364_CR52","doi-asserted-by":"publisher","first-page":"31623","DOI":"10.18632\/oncotarget.9302","volume":"7","author":"A Sriraman","year":"2016","unstructured":"Sriraman A, Radovanovic M, Wienken M, Najafova Z, Li Y, Dobbelstein M. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity. Oncotarget. 2016;7:31623\u201338.","journal-title":"Oncotarget"},{"key":"3364_CR53","doi-asserted-by":"publisher","first-page":"22666","DOI":"10.18632\/oncotarget.4433","volume":"6","author":"C Deben","year":"2015","unstructured":"Deben C, Wouters A, Op de Beeck K, van Den Bossche J, Jacobs J, Zwaenepoel K, et al. The MDM2-inhibitor Nutlin-3 synergizes with cisplatin to induce p53 dependent tumor cell apoptosis in non-small cell lung cancer. Oncotarget. 2015;6:22666\u201379.","journal-title":"Oncotarget"},{"key":"3364_CR54","doi-asserted-by":"publisher","first-page":"2474","DOI":"10.1038\/sj.onc.1203527","volume":"19","author":"T Bowman","year":"2000","unstructured":"Bowman T, Garcia R, Turkson J, Jove R. STATs in oncogenesis. Oncogene. 2000;19:2474\u201388.","journal-title":"Oncogene"},{"key":"3364_CR55","doi-asserted-by":"publisher","first-page":"48296","DOI":"10.18632\/oncotarget.10219","volume":"7","author":"B Tu","year":"2016","unstructured":"Tu B, Zhu J, Liu S, Wang L, Fan Q, Hao Y, et al. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3. Oncotarget. 2016;7:48296\u2013308.","journal-title":"Oncotarget"},{"key":"3364_CR56","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12964-020-0527-z","volume":"18","author":"JH Ma","year":"2020","unstructured":"Ma JH, Qin L, Li X. Role of STAT3 signaling pathway in breast cancer. Cell Commun Signal. 2020;18:33.","journal-title":"Cell Commun Signal"},{"key":"3364_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/1741-7015-10-9","volume":"10","author":"PK Kandala","year":"2012","unstructured":"Kandala PK, Srivastava SK. Diindolylmethane suppresses ovarian cancer growth and potentiates the effect of cisplatin in tumor mouse model by targeting signal transducer and activator of transcription 3 (STAT3). BMC Med. 2012;10:9.","journal-title":"BMC Med"},{"key":"3364_CR58","doi-asserted-by":"publisher","first-page":"3255","DOI":"10.7150\/ijbs.63125","volume":"17","author":"W Lin","year":"2021","unstructured":"Lin W, Sun J, Sadahira T, Xu N, Wada K, Liu C, et al. Discovery and validation of nitroxoline as a novel STAT3 inhibitor in drug-resistant urothelial bladder cancer. Int J Biol Sci. 2021;17:3255\u201367.","journal-title":"Int J Biol Sci"},{"key":"3364_CR59","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1016\/j.eururo.2009.06.028","volume":"56","author":"BW van Rhijn","year":"2009","unstructured":"van Rhijn BW, Burger M, Lotan Y, Solsona E, Stief CG, Sylvester RJ, et al. Recurrence and progression of disease in non-muscle-invasive bladder cancer: from epidemiology to treatment strategy. Eur Urol. 2009;56:430\u201342.","journal-title":"Eur Urol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03364-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03364-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03364-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T14:04:28Z","timestamp":1780322668000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-026-03364-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":59,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,6,20]]}},"alternative-id":["3364"],"URL":"https:\/\/doi.org\/10.1038\/s41416-026-03364-7","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"assertion":[{"value":"18 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}